Disc Medicine Inc (IRON)
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for serious hematologic diseases. The company is working on therapies intended to address biological pathways involved in red blood cell formation and function, with an emphasis on heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria, X-linked protoporphyria, and Diamond-Blackfan anemia; DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease; and DISC-3405 for polycythemia vera and other blood disorders. Disc Medicine also has preclinical programs, including DISC-0998 for anemia linked to inflammatory diseases. Founded in 2017 and based in Watertown, Massachusetts, the company operates in the biotechnology sector and its common stock trades on NASDAQ under the symbol IRON.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IRON
|
$70
|
-6.2% Downside
|
Fair
|
$101.55
|
36.1% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-11.8x
|
4.1x
|
—
|
2.841 B
|
2.157 B
|
1.1%
|
85.7%
|
26.5
|
—
|
83.3%
|
